Clinical Trial

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2025 (before its estimated June 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
Prospective observational study evaluating the safety and accuracy of Feminai 1.0, an at-home adhesive patch that measures skin temperature and electrical impedance to map each breast. Up to 300 women (ages 25-75) undergoing screening will have one study visit; Feminai results will be compared with mammography and, when available, biopsy to assess sensitivity and negative predictive value. Feminai is investigational, intended to support clinical decision-making, and does not replace standard diagnostic tests.
Trial Details
NCT Number NCT07220863
Lead Sponsor Feminai
Conditions Breast Cancer Awareness
Enrollment 300 participants
Start Date 2025-10-05
Primary Completion 2026-06-05 (estimated)
Study Completion 2026-09-05 (estimated)
Updated on ClinicalTrials.gov 2025-10-24